Authors: Akkerhuis, KM van den Brand, MJBM van der Zwaan, C Peels, HOJ Suryapranata, H van der Wieken, LR Stibbe, J Hoffmann, J Baardman, T Deckers, JW Simoons, ML

Citation: Km. Akkerhuis et al., Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty, HEART, 85(4), 2001, pp. 444-450

Authors: Akkerhuis, KM Neuhaus, KL Wilcox, RG Vahanian, A Boland, JL Hoffmann, J Baardman, T Nehmiz, G Roth, U Klootwijk, APJ Deckers, JW Simoons, ML

Citation: Km. Akkerhuis et al., Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation - A phase II study, EUR HEART J, 21(24), 2000, pp. 2042-2055

Authors: Moons, KGM Klootwijk, P Meij, SH van Es, GA Baardman, T Lenderink, T van den Brand, M Habbema, JDF Grobbee, DE Simoons, ML

Citation: Kgm. Moons et al., Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial, AM HEART J, 138(3), 1999, pp. 525-532